CL2017003295A1 - Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias - Google Patents

Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias

Info

Publication number
CL2017003295A1
CL2017003295A1 CL2017003295A CL2017003295A CL2017003295A1 CL 2017003295 A1 CL2017003295 A1 CL 2017003295A1 CL 2017003295 A CL2017003295 A CL 2017003295A CL 2017003295 A CL2017003295 A CL 2017003295A CL 2017003295 A1 CL2017003295 A1 CL 2017003295A1
Authority
CL
Chile
Prior art keywords
lymphocytosis
leukemias
lymphomas
induction
antibodies against
Prior art date
Application number
CL2017003295A
Other languages
English (en)
Inventor
Christian Klein
Carola Ries
Maria Teresa Sabrina Bertilaccio
Giovanni Galletti
CALIGARIS-CAPPIO Federico
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP15173638.6A external-priority patent/EP3108897A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2017003295A1 publication Critical patent/CL2017003295A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A LA LINFOCITOSIS INDUCIDA POR ANTI-CSF-1R EN LINFOMAS Y LEUCEMIAS Y A UNA TERAPIA COMBINADA DE ANTICUERPOS QUE SE UNEN A CSF-1R HUMANO CON ANTICUERPOS QUE SE UNEN A CD20 HUMANO.</p>
CL2017003295A 2015-06-24 2017-12-21 Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias CL2017003295A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15173638.6A EP3108897A1 (en) 2015-06-24 2015-06-24 Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
EP16151129 2016-01-13

Publications (1)

Publication Number Publication Date
CL2017003295A1 true CL2017003295A1 (es) 2018-06-01

Family

ID=56263686

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003295A CL2017003295A1 (es) 2015-06-24 2017-12-21 Anticuerpos contra csf-1r humano para su uso en la inducción de linfocitosis en linfomas o leucemias

Country Status (16)

Country Link
US (1) US20180222985A1 (es)
EP (1) EP3313442B1 (es)
JP (1) JP6811733B2 (es)
KR (1) KR20180012873A (es)
CN (1) CN107847592B (es)
AU (1) AU2016282877A1 (es)
BR (1) BR112017027614A2 (es)
CA (1) CA2987716A1 (es)
CL (1) CL2017003295A1 (es)
CR (1) CR20170537A (es)
IL (1) IL256135A (es)
MX (1) MX2017016651A (es)
PE (1) PE20181050A1 (es)
RU (1) RU2018102575A (es)
WO (1) WO2016207312A1 (es)
ZA (1) ZA201708074B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
KR102629905B1 (ko) 2017-04-01 2024-01-30 베이징 한미 파마슈티컬 컴퍼니 리미티드 항-pd-l1/항-pd-1 천연 항체 구조-유사 헤테로다이머 이중특이성 항체 및 그의 제조
EP3612563A1 (en) 2017-04-19 2020-02-26 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
AU2018314765C1 (en) 2017-08-08 2025-11-20 Bruker Spatial Biology, Inc. Obinutuzumab treatment of a DLBCL patient subgroup
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
CN109053888B (zh) * 2018-07-18 2020-06-19 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及其用途
CN109053886B (zh) * 2018-07-18 2020-07-28 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及用途
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE038955T2 (hu) * 2003-11-05 2018-12-28 Roche Glycart Ag Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval
AU2006290433B2 (en) * 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
DK2510010T3 (en) * 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
AR080698A1 (es) * 2010-04-01 2012-05-02 Imclone Llc Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
BR112013033944A2 (pt) * 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
US20130302274A1 (en) * 2011-11-25 2013-11-14 Roche Glycart Ag Combination therapy
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano

Also Published As

Publication number Publication date
WO2016207312A1 (en) 2016-12-29
CA2987716A1 (en) 2016-12-29
JP2018525339A (ja) 2018-09-06
US20180222985A1 (en) 2018-08-09
BR112017027614A2 (pt) 2018-08-28
EP3313442A1 (en) 2018-05-02
CN107847592B (zh) 2022-01-21
AU2016282877A1 (en) 2018-01-04
RU2018102575A (ru) 2019-07-25
KR20180012873A (ko) 2018-02-06
MX2017016651A (es) 2018-05-14
CN107847592A (zh) 2018-03-27
PE20181050A1 (es) 2018-07-03
AU2016282877A8 (en) 2018-01-18
JP6811733B2 (ja) 2021-01-13
CR20170537A (es) 2018-02-20
EP3313442B1 (en) 2019-10-16
IL256135A (en) 2018-02-28
HK1252860A1 (zh) 2019-06-06
ZA201708074B (en) 2018-11-28

Similar Documents

Publication Publication Date Title
CR20170537A (es) Anticuerpos contra csf-1r humano para uso en la inducción de linfocitosis en linfomas o leucemias.
CL2018002878A1 (es) Composiciones y anticuerpos anti-tim-3.
CL2017002401A1 (es) Anticuerpos contra icos
AR101697A1 (es) Terapia de combinación de inmunocitocinas variantes de il-2 dirigidas a tumores y anticuerpos contra pd-l1 humana
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
MX2022005173A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
MX2023005881A (es) Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
CL2017001361A1 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
MX2020004503A (es) Anticuerpos cd3 humanizados o quimericos.
DOP2016000315A (es) Anticuerpos monoclonales contra el epítope de her2 y sus métodos de uso
BR112016018891A2 (pt) anticorpos anti-dll3 e conjugados de fármacos para uso em melanoma
CL2015002562A1 (es) Anticuerpos e inmunoconjugados anti-b7-h4
DOP2016000153A (es) Anticuerpos y fragmentos anti-vista
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
MX374290B (es) Combinación de un anticuerpo anti cd20 con un inhibidor de btk para usarse en el tratamiento de cáncer.
BR112015032224A2 (pt) anticorpos anti-fcrh5
AR104664A1 (es) Conjugados de fármacos con anticuerpos contra la cadherina 6 (anti-cdh6)
MX370807B (es) Anticuerpos que se unen a axl.
BR112015027309A2 (pt) anticorpo, composição, método de tratamento e uso de um anticorpo
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX2017005553A (es) Terapia de combinacion para cancer.
BR112016029842A2 (pt) conjugados de anticorpo anti-cd22-fármaco e métodos de uso dos mesmos
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2